Literature DB >> 9284738

The hypothalamic-pituitary-adrenocortical axis in severe falciparum malaria: effects of cytokines.

T M Davis1, T A Li, Q B Tran, K Robertson, J R Dyer, T D Phan, D Meyer, M H Beaman, K A Trinh.   

Abstract

Patients with malaria can have features of adrenal insufficiency. Because of the pathophysiological and clinical implications of an Addisonian state, the hypothalamic-pituitary-adrenocortical axis was assessed in nine Vietnamese adults with complicated malaria. A CRH test was performed on admission (in convalescence in five cases) and in six healthy controls. Basal plasma ACTH concentrations in the patients and controls were similar [median (range): 2.9 (0.2-9.7) vs. 3.5 (1.9-13.4) pmol/L, respectively; P > 0.1]. Serum cortisol levels were greater in the patients [882 (294-1682) vs. 190 (110-676) nmol/L; P < 0.01], but three (33%) had values within the control range. Basal serum corticosteroid-binding globulin concentrations were similar in patients and controls (P = 0.23). The post-CRH rise in plasma ACTH was attenuated in the patients [peak: 6.1 (0.9-23.2) vs. 14.5 (6.2-21.5) pmol/L in controls; P < 0.05]; basal and peak plasma ACTH correlated with plasma interleukin-6 in this group (rs > or = 0.60; P < or = 0.04). Serum cortisol responses to CRH were depressed in acute illness [peak 990 (394-1, 805) nmol/L or 10 (0-50%) above baseline vs. 500 (429-703) nmol/L or 160 (10-380%) in controls; P < 0.05]. The median estimated serum cortisol t1/2 was 4.6 h in the patients and 1.6 h in the controls. These data suggest that, relative to a normal stress response, primary and secondary adrenal insufficiency can occur in severe malaria but may be attenuated by increased circulating interleukin-6 concentrations and impaired cortisol metabolism. The benefits of stress-dose corticosteroid replacement are unknown but could be considered in hypoglycemic patients or those with a serum cortisol within or below the reference range.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9284738     DOI: 10.1210/jcem.82.9.4196

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  7 in total

1.  Central diabetes insipidus in a patient with malaria tropica.

Authors:  S Schubert; H Achenbach; L Engelmann; G Borte; M Stumvoll; C A Koch
Journal:  J Endocrinol Invest       Date:  2006-03       Impact factor: 4.256

2.  Cerebral Malaria: An Unusual Cause of Central Diabetes Insipidus.

Authors:  Resmi Premji; Nira Roopnarinesingh; Joshua Cohen; Sabyasachi Sen
Journal:  Case Rep Endocrinol       Date:  2016-05-08

3.  Fever as a cause of hypophosphatemia in patients with malaria.

Authors:  Warren Browner; Richard Haber
Journal:  PLoS One       Date:  2007-12-26       Impact factor: 3.240

4.  Hypopituitarism: A rare sequel of cerebral malaria - Presenting as delayed awakening from general anesthesia.

Authors:  Venkatesh Selvaraj
Journal:  Anesth Essays Res       Date:  2015 May-Aug

5.  Towards Improving Point-of-Care Diagnosis of Non-malaria Febrile Illness: A Metabolomics Approach.

Authors:  Saskia Decuypere; Jessica Maltha; Stijn Deborggraeve; Nicholas J W Rattray; Guiraud Issa; Kaboré Bérenger; Palpouguini Lompo; Marc C Tahita; Thusitha Ruspasinghe; Malcolm McConville; Royston Goodacre; Halidou Tinto; Jan Jacobs; Jonathan R Carapetis
Journal:  PLoS Negl Trop Dis       Date:  2016-03-04

6.  11β-hydroxysteroid dehydrogenase type 1 has no effect on survival during experimental malaria but affects parasitemia in a parasite strain-specific manner.

Authors:  L Vandermosten; C De Geest; S Knoops; G Thijs; K E Chapman; K De Bosscher; G Opdenakker; P E Van den Steen
Journal:  Sci Rep       Date:  2017-10-23       Impact factor: 4.379

7.  Adrenal hormones mediate disease tolerance in malaria.

Authors:  Leen Vandermosten; Thao-Thy Pham; Sofie Knoops; Charlotte De Geest; Natacha Lays; Kristof Van der Molen; Christopher J Kenyon; Manu Verma; Karen E Chapman; Frans Schuit; Karolien De Bosscher; Ghislain Opdenakker; Philippe E Van den Steen
Journal:  Nat Commun       Date:  2018-10-30       Impact factor: 14.919

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.